Bruker Corporation
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Frank H. Laukien
- Full Time Employees
- 11,085
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 40 Manning Road Billerica MA United States 01821
- IPO Date
- Aug 4, 2000
- CIK
- 0001109354
- Website
- bruker.com
- Similar Companies
- Business
- Bruker Corporation (Nasdaq: BRKR) develops, manufactures, and distributes high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore life and materials at molecular, cellular, and microscopic levels. The company offers a broad portfolio of products including nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) spectrometers; mass spectrometry systems; X-ray diffraction, scattering, and microscope analyzers; infrared, near-infrared, and Raman spectroscopy instruments; fluorescence and electron microscopy solutions; preclinical imaging systems; elemental analyzers; surface plasmon resonance systems; microbiology and clinical diagnostic tools such as ClinMASS and ClinDART kits; CBRNE detectors; semiconductor metrology equipment; and laboratory automation, data management, and test & measurement solutions. These products support applications in life science molecular research, pharmaceuticals, biotechnology, materials science, microscopy and nanoanalysis, industrial quality control, preclinical imaging, clinical phenomics and proteomics, and clinical microbiology. Founded in 1960 and headquartered in Billerica, Massachusetts, Bruker operates globally with over 11,000 employees across more than 90 locations on all continents, serving academic, governmental, pharmaceutical, biotechnology, and industrial customers. In April 2025, Bruker announced a majority investment in RECIPE Chemicals + Instruments GmbH, a Munich-based provider of clinical diagnostic assays, enhancing its small molecule diagnostics capabilities through integration of RECIPE's ClinMASS kits for EVOQ liquid chromatography triple-quadrupole mass spectrometers and upcoming high-throughput ClinDART kits for chromatography-free workflows on EVOQ-DART systems. Earlier, in 2024, the company acquired Dynamic Biosensors GmbH to strengthen its biosensor portfolio for molecular interaction analysis, complementing high-performance surface plasmon resonance systems like SPR #64 'Triceratops' for pharmaceutical and biotechnology drug discovery. Bruker also secured approximately $10 million in federally funded NMR system orders in October 2025 from institutions including the New York Structural Biology Center, University of Delaware, and Northwestern University, while initiating a major cost savings program targeting $100-120 million in annual reductions by fiscal 2026 amid market pressures.
Company News
Bruker Announces Date and Time of Third Quarter 2026 Earnings Release and Webcast
Is Bruker Corp (BRKR) a Bargain After 3.1% Drop? GF Value Says Undervalued
Bruker Gains 66.3% in a Year: What's Driving the Rally?
Bruker Corp (BRKR) Shares Fall 5.3% -- GF Value Says Still Overvalued
Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution
Why Bruker (BRKR) is a Top Momentum Stock for the Long-Term
Bruker (NASDAQ:BRKR) Sets New 1-Year High – Should You Buy?
Neuralink Stock: How to Invest Before the IPO
Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research
Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research
Bruker Sees AI-Fueled Semiconductor Demand, Targets Critical Q4 Revenue Rebound
Bruker Corporation (BRKR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Bruker Receives Order for High-Field NMR Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley
Bruker Corporation (BRKR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Bruker Corporation (BRKR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Bruker Corporation to Present at Upcoming Investor Conferences
Bruker Corporation to Present at Upcoming Investor Conferences
BEST and Luvata Announce Collaboration Agreement for Supply of High-Performance RRP® Superconductors for Magnetic Confinement Fusion
BEST and Luvata Announce Collaboration Agreement for Supply of High-Performance RRP® Superconductors for Magnetic Confinement Fusion
Why Is Bruker (BRKR) Up 12.5% Since Last Earnings Report?